Sirtuin-4 (SIRT4) is downregulated and associated with some clinicopathological features in gastric adenocarcinoma

Biomedicine and Pharmacotherapy

Volumn 72, Issue , 2015, Pages 135-139

  Huang, Guoyu ^a   Cui, Feifei ^a   Yu, Fudong ^a   Lu, Huijun ^a   Zhang, Meng ^a   Tang, Huamei ^a   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Carcinogenesis; Gastric adenocarcinoma; SIRT4

Indexed keywords

SIRTUIN 4; MITOCHONDRIAL PROTEIN; SIRT4 PROTEIN, HUMAN; SIRTUIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; TISSUE MICROARRAY; TUMOR INVASION; ADENOCARCINOMA; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH; STOMACH TUMOR; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; SIRTUINS; STOMACH; STOMACH NEOPLASMS;

EID: 84930519237     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.04.013     Document Type: Article

References (26)

1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513(7517):202-209.
2. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J. Gastrointest. Oncol. 2012, 4(7):156-169.
3. Zang Z.J., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 2012, 44(5):570-574.
4. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460(7255):587-591.
5. Yuan H., Su L., Chen W.Y. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Oncol. Targets Ther. 2013, 6:1399-1416.
6. Brunet A., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303(5666):2011-2015.
7. Chen W.Y., et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123(3):437-448.
8. Haigis M.C., et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006, 126(5):941-954.
9. Nasrin N., et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J. Biol. Chem. 2010, 285(42):31995-32002.
10. Ahuja N., et al. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J. Biol. Chem. 2007, 282(46):33583-33592.
11. Jeong S.M., et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23(4):450-463.
12. Csibi A., et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013, 153(4):840-854.
13. Chen J., et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011, 71(12):4138-4149.
14. Roth M., Chen W.Y. Sorting out functions of sirtuins in cancer. Oncogene 2013.
15. Noguchi A., et al. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. 2014, 3(6):1553-1561.
16. Stunkel W., et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J. 2007, 2(11):1360-1368.
17. Huffman D.M., et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007, 67(14):6612-6618.
18. Hida Y., et al. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res. 2007, 299(2):103-106.
19. Wang R.H., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008, 14(4):312-323.
20. Firestein R., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008, 3(4):e2020.
21. Jeong S.M., et al. SIRT4 suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J. Biol. Chem. 2013.
22. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
23. Boroughs L.K., DeBerardinis R.J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell. Biol. 2015.
24. Daye D., Wellen K.E. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 2012, 23(4):362-369.
25. Tennant D.A., Duran R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10(4):267-277.
26. Mathias R.A., et al. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell 2014, 159(7):1615-1625.